Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

PHASE4RecruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Wangbi granules

Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.

DRUG

Wangbi granules simulant

Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.

Trial Locations (1)

100029

RECRUITING

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

collaborator

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

OTHER

collaborator

The 980th Hospital of PLA Joint Logistics Support Force

UNKNOWN

collaborator

The Second Affiliated Hospital of Zhejiang Chinese Medical University

OTHER

collaborator

Southwest Hospital, China

OTHER

lead

China-Japan Friendship Hospital

OTHER